MKI67 Antibodies

Structure of MKI67

MKI67 is a large nucleoprotein with a molecular weight of approximately 359 kDa. This protein is encoded by a gene of up to 11,423 bases, and its molecular weight can vary significantly due to the differences in the splicing methods of the transcript among different species.

This protein contains multiple characteristic domains, among which the most important one is the "Ki67 domain" encoded by exon 13, which forms a typical coil-coil conformation. The N-terminal and C-terminal regions respectively contain highly conserved PP1 phosphorylation sites and tandem repeat sequences. These repeat units mediate the interaction between the protein and chromatin by forming specific spatial conformations. Its secondary structure is mainly composed of α -helices, which are assembled into a typical bull-shaped form through flexible junction regions, enabling it to dynamically bind to the chromosome surface during cell division.

Fig. 1 Interactions between MKI67 and eight genes related to P53 signaling pathway.¹

Key structural properties of MKI67:

• Contains large coiled helical domains
• Modules with tandem repeats are used for chromatin binding
• Contains multiple PP1 phosphorylation sites to regulate cell cycle
• Form a bull-shaped dimer structure to scan the surface of chromosomes

Functions of MKI67

The core function of the MKI67 gene is to serve as a marker for cell proliferation. However, it is also directly involved in a variety of key cell cycle processes, including the maintenance of chromosomal organization and the regulation of mitosis.

Unlike cyclins that only function at specific cycle stages, the expression of MKI67 is continuous throughout the entire cycle. This unique dynamic pattern makes it a "molecular ruler" for precisely quantifying the proportion of proliferating cells in complex tissues.

Applications of MKI67 and MKI67 Antibody in Literature

1. Saeed, Muhammad Muddasar, et al. "RACGAP1 and MKI67 are potential prognostic biomarker in hepatocellular carcinoma caused by HBV/HCV via lactylation." Frontiers in Oncology 15 (2025): 1537084. https://doi.org/10.3389/fonc.2025.1537084

This study found through sequencing that MKI67 is a key gene for pulmonary arterial hypertension. Experiments have confirmed that inhibiting MKI67 can significantly reduce the proliferation and migration of pulmonary artery smooth muscle cells, indicating its potential as a new target for the diagnosis and treatment of pulmonary arterial hypertension.

2. Wu, Shi-yi, et al. "Correlation of MKI67 with prognosis, immune infiltration, and T cell exhaustion in hepatocellular carcinoma." BMC gastroenterology 21.1 (2021): 416. https://doi.org/10.1186/s12876-021-01984-2

Research has found that MKI67 is a key gene regulating the proliferation and migration of pulmonary artery smooth muscle cells. Inhibiting its expression can slow down the lesion process, indicating that MKI67 is expected to become a new diagnostic and therapeutic target for pulmonary arterial hypertension.

3. Xiong, Dan-dan, et al. "Ki-67/MKI67 as a predictive biomarker for clinical outcome in gastric cancer patients: an updated meta-analysis and systematic review involving 53 studies and 7078 patients." Journal of Cancer 10.22 (2019): 5339. https://doi.org/10.7150/jca.30074

Studies have found that gastric cancer patients with high expression of Ki-67/MKI67 have a poorer overall survival period, and it is significantly associated with adverse features such as advanced tumor and lymph node metastasis. It can serve as a potential indicator for prognosis prediction and identification of high-risk cases.

4. Pan, Xiaolan, et al. "A comprehensive analysis of the prognostic value, expression characteristics and immune correlation of MKI67 in cancers." Frontiers in Immunology 16 (2025): 1531708. https://doi.org/10.3389/fimmu.2025.1531708

Pan-cancer analysis shows that MKI67 is highly expressed in various cancers and is significantly associated with poor prognosis in patients with lung adenocarcinoma and liver cancer. It also involves pathways such as the cell cycle and p53, and has important clinical prognostic guidance value.

5. Zhou, Huiling, et al. "MKI67 as a potential diagnostic biomarker in pulmonary hypertension." Frontiers in Pediatrics 10 (2022): 1016889. https://doi.org/10.3389/fped.2022.1016889

Research has found that MKI67 is a key gene regulating the proliferation and migration of pulmonary artery smooth muscle cells. Inhibiting its expression can slow down the progression of the disease and is expected to become a new target for the diagnosis and treatment of pulmonary arterial hypertension.

Creative Biolabs: MKI67 Antibodies for Research

Creative Biolabs specializes in the production of high-quality MKI67 antibodies for research and industrial applications. Our portfolio includes monoclonal antibodies tailored for ELISA, Flow Cytometry, Western blot, immunohistochemistry, and other diagnostic methodologies.

• Custom MKI67 Antibody Development: Tailor-made solutions to meet specific research requirements.
• Bulk Production: Large-scale antibody manufacturing for industry partners.
• Technical Support: Expert consultation for protocol optimization and troubleshooting.
• Aliquoting Services: Conveniently sized aliquots for long-term storage and consistent experimental outcomes.

For more details on our MKI67 antibodies, custom preparations, or technical support, contact us at email.